Since joining Kirkland, Zohra has been involved in the following matters:
- Avidity Biosciences in its $12 billion sale to Novartis, and the related spin-off of its early-stage precision cardiology programs
- Akero Therapeutics in its sale to Novo Nordisk for up to $5.2 billion
Prior to joining Kirkland, Zohra was involved in the following matters:
- Chimerix in its $935 million sale to Jazz Pharmaceuticals
- Evergreen Theragnostics in its sale to Lantheus for up to $1 billion
- Vertex Pharmaceuticals in its $4.9 billion acquisition of Alpine Immune Sciences
- Ambrx Biopharma in its $2 billion acquisition by Johnson & Johnson
- POINT Biopharma in its $1.4 billion acquisition by Eli Lilly
- CTI Biopharma in its $1.7 billion acquisition by Swedish Orphan Biovitrum
- BELLUS Health in its $2 billion sale to GSK
